Announcement of GUDID Release 2.2 Deployment and Document Updates

By AHRMM

GUDID Release 2.2 was successfully deployed. The enhancements will allow for additional functionality as noted below.

  • Labelers will be able to “unlock” their device records after the DI record grace period to make error corrections. This will eliminate the need to contact the FDA UDI Help Desk to make corrections after the grace period.

Note that the Unlock functionality is intended to be used to correct data submission errors after the grace period. DO NOT USE Unlock functionality for edits that require assignment of a NEW Device Identifier. Please assign a new Device Identifier and submit a new record if you are changing data elements that are “New DI Triggers” (i.e., not correcting submission errors)

  • Addition of new data elements to the GUDID download file made available on AccessGUDID and OpenFDA to include –
  • Public Version Number
  • Public Version Date
  • Public Version Status (new/update/delete)
  • Public Device Record Key
  • Labeler DUNS Number
  • Premarket Submission Number & Supplement Number – note that this will be released after the testing/review period as indicated here.

GUDID documents (listed below) have been updated as of March 30, 2018.

We have also updated the GUDID System Enhancements and Fixes page to reflect all releases to-date.

If you have questions, concerns or feedback, please contact the FDA UDI Help Desk.

 

Related Resources

Supply Chain Strategies & Solutions Article
Implementing a Low Unit of Measure (LUM) program at your organization has many benefits beyond reducing inventory.  LUM can act as a cat
Supply Chain Strategies & Solutions Article
Blockchain technology provides a promising future for health care by improving the transparency in products and processes while providing adv
Toolkits/Methodology
AHRMM’s Learning UDI Community (LUC) is a health care collaborative effort, in collaboration with the U.S.
White Papers
In an effort to capture broader insights on UDI adoption from across the health care field, AHRMM, with participation by the FDA, held LUC Dat
Toolkits/Methodology
With significant pressures on hospitals and healthcare systems, it is incumbent upon those who recognize the benefits of UDI to build the business